Skip to content


Opdivo (nivolumab) is an antibody pharmaceutical. Nivolumab was first approved as Opdivo on 2014-12-22. It is used to treat kidney neoplasms, lymphoma, melanoma, non-small-cell lung carcinoma, and squamous cell carcinoma amongst others in the USA. It has been approved in Europe to treat colorectal neoplasms, hodgkin disease, melanoma, mesothelioma, and non-small-cell lung carcinoma amongst others. The pharmaceutical is active against programmed cell death protein 1.
Trade Name Opdivo
Common Name Nivolumab
Indication colorectal neoplasms, hodgkin disease, kidney neoplasms, lymphoma, melanoma, mesothelioma, non-small-cell lung carcinoma, renal cell carcinoma, squamous cell carcinoma, squamous cell carcinoma of head and neck, transitional cell carcinoma, urinary bladder neoplasms, urologic neoplasms
Drug Class Monoclonal antibodies: fully human, immunomodulating
Get full access now